{"id":798069,"date":"2026-08-01T21:09:14","date_gmt":"2026-08-01T21:09:14","guid":{"rendered":"https:\/\/www.newsbeep.com\/us\/798069\/"},"modified":"2026-08-01T21:09:14","modified_gmt":"2026-08-01T21:09:14","slug":"new-hiv-pill-delivers-breakthrough-results-in-first-human-trial","status":"publish","type":"post","link":"https:\/\/www.newsbeep.com\/us\/798069\/","title":{"rendered":"New HIV Pill Delivers Breakthrough Results In First Human Trial"},"content":{"rendered":"<p>A promising new HIV treatment has passed its first test in people, giving researchers hope for another effective way to fight the virus. The drug, known as VH-499, is designed to stop HIV-1 from multiplying inside the body. It works by targeting the virus&#8217;s capsid protein, which forms a protective shell around the virus and is essential for its survival and spread.<\/p>\n<p>Scientists recently completed a Phase 2a clinical trial involving 23 adults with HIV-1 who had not yet started standard HIV treatment. Twenty participants received different doses of VH-499, while three received a placebo.<\/p>\n<p>Before treatment, all participants had high levels of HIV in their blood. After taking VH-499, every participant who received the drug experienced a drop in viral load by the eleventh day of the study. Those given higher doses generally saw larger reductions. In contrast, the placebo group showed very little change.<\/p>\n<p>Researchers reported that VH-499 was well tolerated and showed a favourable safety profile. The findings suggest the drug has strong antiviral activity and could become an important addition to HIV treatment options.The research is published in <a class=\"sp_lnk2\" href=\"https:\/\/academic.oup.com\/cid\/advance-article\/doi\/10.1093\/cid\/ciag452\/8747010\" rel=\"nofollow sponsored noopener\" target=\"_blank\">Clinical Infectious Diseases.<\/a><\/p>\n<p>One reason scientists are interested in VH-499 is that it appears to have fewer interactions with CYP3A4, an enzyme that plays a role in processing many medicines. Drug interactions can be a challenge for people who take several medications for different health conditions.<\/p>\n<p>The new drug is being compared with lenacapavir, another capsid inhibitor already used for HIV treatment and prevention. While lenacapavir can provide protection for up to six months with a single injection, it can interact with certain medications. Researchers believe VH-499 could be a useful alternative for people who have complex treatment needs.<\/p>\n<p>Although the results are encouraging, the drug still has a long way to go before reaching patients. Larger Phase 3 trials will be needed to confirm its safety and effectiveness and to compare it directly with existing HIV treatments.<\/p>\n<p>If future studies are successful, VH-499 could help expand the range of long-acting HIV therapies and support global efforts to reduce HIV transmission in the years ahead.<\/p>\n","protected":false},"excerpt":{"rendered":"A promising new HIV treatment has passed its first test in people, giving researchers hope for another effective&hellip;\n","protected":false},"author":2,"featured_media":798070,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[34],"tags":[338698,281152,338699,771,97,12992,338697,338703,13299,338702,338704,13304,338695,8871,338039,253398,237896,338701,5599,338696,338700],"class_list":["post-798069","post","type-post","status-publish","format-standard","has-post-thumbnail","category-health","tag-antiretroviral-therapy","tag-antiviral-drug","tag-capsid-inhibitor","tag-clinical-trial","tag-health","tag-hiv","tag-hiv-drug","tag-hiv-medicine","tag-hiv-prevention","tag-hiv-research","tag-hiv-therapy","tag-hiv-treatment","tag-hiv-1","tag-infectious-diseases","tag-lenacapavir","tag-medical-breakthrough","tag-pharmaceutical-research","tag-phase-2a-trial","tag-public-health","tag-vh-499","tag-viral-load"],"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/posts\/798069","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/comments?post=798069"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/posts\/798069\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/media\/798070"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/media?parent=798069"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/categories?post=798069"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/tags?post=798069"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}